Abbott returns Flutiform to SkyePharma

Abbott Laboratories (NYSE:ABT) terminated a 2006 deal and returned to SkyePharma plc (LSE:SKP) U.S. rights for Flutiform fluticasone/formoterol. SkyePharma said in June that "significant additional work" would be required prior to approval of the product for asthma. FDA issued a complete response letter in January requesting data that would require additional clinical work. SkyePharma said it is investigating whether there is a viable way forward for Flutiform in the U.S. If it does decide to move forward, the company would seek a new U.S. partner to finance any additional clinical work required. ...